Ectopic ACTH syndrome – Experience with Etomidate*

For ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS), when surgery is not feasible, or in cases of severe biochemical disturbances, immunosuppression or mental instability, medical therapy with agents such as etomidate is indicated. We present our experience in using etomidate for a 41-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Chin Voon, Hussein, Zanariah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of the ASEAN Federation of Endocrine Societies 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784153/
https://www.ncbi.nlm.nih.gov/pubmed/33442086
http://dx.doi.org/10.15605/jafes.032.01.10
_version_ 1783632249041715200
author Tong, Chin Voon
Hussein, Zanariah
author_facet Tong, Chin Voon
Hussein, Zanariah
author_sort Tong, Chin Voon
collection PubMed
description For ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS), when surgery is not feasible, or in cases of severe biochemical disturbances, immunosuppression or mental instability, medical therapy with agents such as etomidate is indicated. We present our experience in using etomidate for a 41-year old female with EAS secondary to a malignant mediastinal paraganglioma. We were able to demonstrate that etomidate can be used effectively to control severe hypercortisolism in a lower dose than previously described.
format Online
Article
Text
id pubmed-7784153
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Journal of the ASEAN Federation of Endocrine Societies
record_format MEDLINE/PubMed
spelling pubmed-77841532021-01-12 Ectopic ACTH syndrome – Experience with Etomidate* Tong, Chin Voon Hussein, Zanariah J ASEAN Fed Endocr Soc Case Report For ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS), when surgery is not feasible, or in cases of severe biochemical disturbances, immunosuppression or mental instability, medical therapy with agents such as etomidate is indicated. We present our experience in using etomidate for a 41-year old female with EAS secondary to a malignant mediastinal paraganglioma. We were able to demonstrate that etomidate can be used effectively to control severe hypercortisolism in a lower dose than previously described. Journal of the ASEAN Federation of Endocrine Societies 2017-04-21 2017 /pmc/articles/PMC7784153/ /pubmed/33442086 http://dx.doi.org/10.15605/jafes.032.01.10 Text en © 2017 Journal of the ASEAN Federation of Endocrine Societies https://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International.
spellingShingle Case Report
Tong, Chin Voon
Hussein, Zanariah
Ectopic ACTH syndrome – Experience with Etomidate*
title Ectopic ACTH syndrome – Experience with Etomidate*
title_full Ectopic ACTH syndrome – Experience with Etomidate*
title_fullStr Ectopic ACTH syndrome – Experience with Etomidate*
title_full_unstemmed Ectopic ACTH syndrome – Experience with Etomidate*
title_short Ectopic ACTH syndrome – Experience with Etomidate*
title_sort ectopic acth syndrome – experience with etomidate*
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784153/
https://www.ncbi.nlm.nih.gov/pubmed/33442086
http://dx.doi.org/10.15605/jafes.032.01.10
work_keys_str_mv AT tongchinvoon ectopicacthsyndromeexperiencewithetomidate
AT husseinzanariah ectopicacthsyndromeexperiencewithetomidate

Ejemplares similares